Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 14/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477887 | 0.93 | CES2 (0.42) | CES2KDM4ERAB9AL3MBTL1EP300 | |
| SCHEMBL6818421 | 0.91 | CES2 (0.36) | CES2KDM4ERAB9AL3MBTL1EP300 | |
| SCHEMBL6476790 | 0.71 | CES2 (0.45) | CES2KDM4ERAB9AL3MBTL1EP300 | |
| SCHEMBL13104005 | 0.61 | CES2 (1.00) | CES2KDM4ERAB9AL3MBTL1 | |
| SCHEMBL4240299 | 0.59 | CES2 (0.76) | CES2KDM4ERAB9AL3MBTL1KMT2A | |
| SCHEMBL4059748 | 0.56 | CES2 (0.82) | CES2KDM4ERAB9AL3MBTL1 | |
| SCHEMBL19499378 | 0.56 | CES2 (0.89) | CES2KDM4ERAB9AL3MBTL1MEN1 | |
| SCHEMBL4435666 | 0.56 | KMT2A (0.72) | CES2KDM4EL3MBTL1EP300MEN1 | |
| SCHEMBL17070921 | 0.55 | KDM4E (0.69) | CES2KDM4EEP300MEN1KMT2A | |
| SCHEMBL1088583 | 0.55 | EP300 (0.46) | CES2EP300MEN1KMT2AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | CES2 2239/4885KDM4E 1218/4885RAB9A 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.